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Abstract
Background: Genomic instability and clonal evolution are hallmarks of progressing chronic myeloid leukemia
(CML). Recently, we have shown that clonal evolution and blast crisis correlate with altered expression and activity
of Separase, a cysteine endopeptidase that is a mitotic key player in chromosomal segregation and centriole
duplication. Hyperactivation of Separase in human hematopoietic cells has been linked to a feedback mechanism
that posttranslationally stimulates Separase proteolytic activity after imatinib therapy-induced reduction of Separase
protein levels.
Methods and Results: In search for potential therapy-responsive transcriptional mechanisms we have investigated
the role of the transcription factor c-MYB for Separase expression in CML cell lines (LAMA-84, K562, BV-173) and in
clinical samples. Quantitative RT-PCR and Western blot immunostaining experiments revealed that c-MYB expression
levels are decreased in an imatinib-dependent manner and positively correlate with Separase expression levels in cell
lines and in clinical CML samples. RNA silencing of c-MYB expression in CML cell lines resulted in reduced Separase
protein levels. Gelshift and ChIP assays confirmed that c-MYB binds to a putative c-MYB binding sequence located
within the ESPL1 promoter.
Conclusions: Our data suggest that ESPL1/Separase is a regulatory target of c-MYB. Therefore, c-MYB, known to be
required for BCR-ABL-dependent transformation of hematopoietic progenitors and leukemogenesis, may also control
the Separase-dependent fidelity of mitotic chromosomal segregation and centriole duplication essential for
maintenance of genomic stability.
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Background
ESPL1/Separase, a cysteine endopeptidase, is a key player
of chromosomal segregation and centrosome duplica-
tion. In mitotic anaphase, it accomplishes proteolytic
cleavage of Cohesin, a “glue” multi-protein complex that
is responsible for cohesion of sister chromatids and of
mother and daughter centrioles, the perpendicular
oriented core structures of centrosomes [1–3]. Proper
temporal and spatial activation of Separase proteolytic
activity warrants chromosomal fidelity by establishing an
accurate chromosomal segregation [4]. Furthermore, it is
an essential prerequisite for semiconservative centriole
duplication as the disengagement of mother and daugh-
ter centrioles licenses the cell cycle-associated duplica-
tion of centrosomes [5]. Failure to do so will result in
premature segregation of chromatids and/or formation
of anaphase bridges from lagging chromosomes [6].
Moreover, unscheduled (cell cycle uncoupled) activation
of Separase can lead to aberrant high numbers of centro-
somes (i.e. centrosome amplification) and subsequently to
a defective mitotic spindle apparatus [7]. Both defects
cause the emergence of aberrant karyotypes (aneuploidy),
a hallmark of most advanced human malignancies [8–10].
In non-malignant cells where chromosome segregation
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and centrosomal duplication are tightly coupled to the cell
cycle, Separase is temporary activated on metaphase to
anaphase transition [11, 12]. Separase is tightly regulated
on both translational and posttranslational levels. The lat-
ter includes multiple inhibitory mechanisms combining
Securin binding, specific serine residue phosphorylation
(pSer1126) by CyclinB1/CDK1, autocatalytic cleavage, and
PP2A-dependent stabilization of Separase-bound Securin.
All these mechanisms work together to prevent ectopic
and unscheduled activation of intracellular Separase
molecules [13–16].
In human cancer, ESPL1/Separase is frequently overex-
pressed and the resulting deregulated proteolytic activity
is associated with the occurrence of supernumerary cen-
trosomes, chromosomal missegregation and aneuploidy
[6, 9, 13, 17]. Overexpression of Separase in the mammary
gland of a MMTV-ESPL1 mouse model led to the devel-
opment of highly aneuploid mammary carcinomas with
high levels of chromosomal instability and aggressive
disease phenotypes [18]. Consequently, Separase has been
identified as an aneuploidy promoter that, when over-
expressed and hyperactive, functions as an oncogene
and renders cells susceptible not only for chromo-
somal missegregation-induced aneuploidy but also for
DNA damage and loss of key tumor suppressor gene
loci associated with tumorigenesis and disease pro-
gression [18–20].
This holds true for chronic myeloid leukemia (CML) as
well, a clonal neoplastic disorder of hematopoietic stem
cells caused by the genomic reciprocal translocation
t(9;22)(q34;q11), which results in the formation of the
Philadelphia chromosome. The fusion product, a BCR-
ABL tyrosine kinase (TK) with deregulated TK activity, is
the key player in CML pathogenesis. It affects various
downstream signaling pathways by reprogramming the
prior lineage commitment of hematopoietic stem and
early progenitor cells [21]. Compromising multiple aspects
of cellular behavior, including proliferation, apoptosis, cell
to cell signaling and differentiation, the BCR-ABL onco-
protein triggers aberrant clonal hematopoiesis and drives
disease progression from chronic phase (CP) toward the
fully transformed phenotype of blast crisis (BC) [22]. Ima-
tinib (IM) is a selective TK inhibitor (TKI) and presents
one of the current first line treatments for CML [23, 24].
Despite significant decreases in BCR-ABL mRNA levels in
the bone marrow compartment under IM long-term ther-
apy, persistence of residual CML clones with low BCR-
ABL expression and insensitivity to IM treatment makes
disease eradication by TKI treatment unlikely [13, 25, 26].
Recent evidence suggests that kinase activity of BCR-ABL
oncoprotein in CML stem cells is inhibited by TKI treat-
ment without affecting CML stem cell survival [27, 28].
Obviously, additional cellular mechanisms promote CML
stem cell survival and maintenance, rendering these cells
TKI resistant and eventually promote relapse [29, 30].
About 35 % of patients in CP develop resistance or
intolerance to IM and frequently undergo clonal evolu-
tion [31]. Clonal evolution denotes a heterogeneous
entity of clonal molecular changes in BCR-ABL-positive
hematopoietic stem/progenitor cells and has been
described in about 30 % and 80 % of patients in acceler-
ated phase (AP) and BC, respectively [32]. Emergence
of altered chromosome numbers, collectively termed
aneuploidy, involves an additional derivative chromo-
some 22, chromosome 17 abnormalities, trisomy 8, and
are associated with poor prognosis [33, 34].
Recently, we have reported that enhanced rates of
acquired chromosomal aberrations, clonal evolution and
fast disease progression (time to BC) in CML patients
undergoing long-term IM treatment correlate with en-
hanced proteolytic activity of Separase in the respective
in vitro models [35]. Mechanistically, this was linked to
a BCR-ABL-dependent regulatory feedback mechanism
that posttranslationally stimulates Separase proteolytic
activity after IM-induced decreases of Separase expres-
sion in b3a2 BCR-ABL fusion type CML cell lines [35].
To date, it was unclear what underlying transcriptional
or translational mechanism may be involved in the IM-
dependent regulation of Separase expression in BCR-
ABL-positive cells.
The transcription factor c-MYB is known to play an im-
portant role in BCR-ABL-dependent leukemogenesis. The
expression of c-MYB is enhanced by BCR-ABL [36–38]. C-
MYB is a 75 KDa nuclear protein and a leucine zipper tran-
scription factor encoded by the proto-oncogene c-MYB. It
plays a pivotal role in proliferation, survival and differenti-
ation of normal myeloid progenitors [39]. Conditional
knockout of c-MYB expression in adult hematopoietic stem
cells causes loss of self-renewal due to impaired prolifera-
tion and accelerated differentiation [40]. On the other
hand, overexpression of c-MYB in myeloid and erythroid
cell lines has been demonstrated to block differentiation
and prevents maturation-associated growth arrest [41].
Aberrant (enhanced) c-MYB expression has been found in
various human malignancies including T-cell leukemia and
acute and chronic myeloid leukemias [42]. Moreover,
various genetic lesions affecting c-MYB activity in human
leukemias, such as chromosomal translocation, gene dupli-
cation and truncations have been reported [39, 43, 44].
However, in CML cells, the c-MYB gene has been reported
to be intact but protein levels are often increased, in part,
due to enhanced protein stability via BCR-ABL-regulated
activation of PI-3 K/Akt/GSKIIIß dependent pathways [36].
This altered regulatory mechanism has been considered to
explain why leukemic blast cells appear to depend on high
c-MYB expression levels more than their normal counter-
parts [45]. Functional studies of c-MYB by ChIP-Seq exper-
iments revealed that c-MYB functions as a hematopoietic
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master regulator [46]. It binds directly near or within 793
genes thereby affecting more than 2300 genes that make
up the gene signatures for normal and leukemic stem/pro-
genitor cells and myeloid development. Despite being
usually considered as a transactivator, c-MYB is also able to
directly repress many target genes pointing to an important
role for myelopoiesis and leukemogenesis through both
positive and negative transcriptional regulation [47]. For
example, c-MYB modulates the expression of CD34, c-Kit,
c-Myc, Flt-3 and Bcl-2 all playing important roles for prolif-
eration and survival of hematopoietic cells [38]. Moreover,
c-MYB directly regulates CyclinB1 expression and contrib-
utes to the control of the G2/M cell cycle phase [48, 49],
thereby directly controlling one of the key posttranslational
inhibitors of Separase [13, 14].
In this study, we set out to investigate the role of c-
MYB for the regulation of ESPL1/Separase expression
in CML. We report that c-MYB binds to a c-MYB
binding motif located within the ESPL1 promoter and
functions as a positive regulator of ESPL1/Separase
expression as demonstrated by c-MYB-directed siRNA
silencing. Moreover, IM treatment led to equally de-
creased c-MYB and ESPL1/Separase expression levels
in CML cell lines and primary cells.
Results
In search for transcriptional mechanisms that could
explain the IM-associated downregulation of Separase
protein levels we analyzed the conditional context
between c-MYB expression, Separase and IM treatment.
Confirming and expanding previously published work
we performed cell culture experiments on four human
cell lines [13, 35]. Of these, U937 cells served as model
for leukemic but BCR-ABL-negative cells. All cell lines
were treated with therapeutic doses of IM (1 to 5 μM) as
performed in our previous studies [13, 50–52]. In
accordance with data from extensive studies on the
dose-dependent effects and time kinetics of IM we
applied lower IM doses (range: 1 to 2.5 μM) for
leukemia-derived p210BCR-ABL-positive cells (LAMA-
84 and K562) than for p210BCR-ABL-negative cells
(U937, 5 μM) [53, 54]. Treating CML cell lines with IM
doses higher than 2.5 μM for a longer period than 24 h
impeded the collection of sufficient viable cells for
Western blot analysis (data not shown).
Concerted decrease of c-MYB and ESPL1 expression levels
under IM treatment
Treatment of the CML cell lines LAMA-84 and K562
with therapeutic IM doses for 24 h revealed decreased ex-
pression levels for c-MYB and ESPL1/Separase on both
transcriptional and protein levels as shown on representa-
tive Western blot composite images (Fig. 1, Table 1). It
should be emphasized that the weak treatment schedule
(≤2.5 μM IM for 24 h) still enabled CrkL phosphorylation
(Fig. 1, lower panel). Thus, when compared to the re-
spective untreated cells, the decreasing c-MYB protein
levels in LAMA-84 (−25.7 ± 9.6 %) and K562 (−37.1 ±
Fig. 1 Analysis of c-MYB and ESPL1 transcript levels, c-MYB and Separase protein levels in LAMA-84 (a), K562 (b) and BCR-ABL-negative control
cells (U937) (c) upon IM treatment. Treatment (dose, period) was performed as noted in Table 1. Level changes (Δ-values in %) are shown as cal-
culated from comparison with the corresponding untreated cells. Upper panel. Transcript levels were analyzed by qRT-PCR, protein levels by West-
ern blot immunostaining densitometry. Representative Western blot images are shown in the lower panel. In all qRT-PCR experiments the
housekeeping gene Gus (beta-glucuronidase) served as internal standard. For Western blot immunostaining experiments Actin was used as load-
ing control and reference parameter. Densitometric data are derived from at least triplicate experiments and are denoted in Table 1. P-values are
given above the respective column. Abbreviations: ns, not significant; nd, not determined
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9.6 %) cells concurred with decreased ESPL1 transcript
levels of −90 ± 3.3 % and −25.0 ± 9.7 %, respectively.
One might argue that the observed decline may be due
to IM-related changes in the cell cycle. However, FACS
analysis of tested cells revealed no differences neither
in G2/M cell proportion nor in the apoptotic cell frac-
tion (<12 %) that could clarify the observed decreases
in c-MYB and ESPL1/Separase expression levels (com-
pare Fig. 3b in Ref. [13]). Treatment of BCR-ABL-negative
control cells (U937) with IM revealed no changes in c-
MYB protein and ESPL1/Separase expression levels
(Table 1, Fig. 1).
Similar results were obtained when paired clinical sam-
ples (n = 5), each pair derived from the same CML patient
before (at diagnosis) and during IM therapy were com-
paratively monitored for c-MYB and ESPL1 transcript
levels (Fig. 2). Two female and three male patients, all
with b3a2 BCR-ABL fusion type, were analyzed. The
median age was 58 years (range, 47 to 78). Mean time be-
tween diagnosis and sampling of the second specimen
from the same patient after achievement of MMR under
IM treatment was 3.6 years (range, 2 to 6.5). These experi-
ments suggest synchronous regulatory mechanisms for c-
MYB and ESPL1/Separase expression upon IM treatment
in vitro and in vivo.
Decreased Separase expression levels after c-MYB
silencing in CML cell lines
To test the direct regulatory influence of c-MYB on Separ-
ase expression we silenced c-Myb transcription in LAMA-
84 and BV-173 cells and monitored the influence of the
resulting decline in c-MYB protein levels on Separase ex-
pression (Fig. 3). The siRNA-induced decrease in available
c-MYB molecules resulted in decreased c-MYB protein
levels in BV-173 (−49 ± 13.6 %) and LAMA-84 cells
(−47.6 ± 7.9 %). This suggests a direct regulatory relation-
ship between c-MYB and ESPL1/Separase.
c-MYB binds to a putative c-MYB recognition site located
within the ESPL1 promoter
The ESPL1 promoter features two hormone responsive el-
ements and two TP53 binding sites that are located 12,777
and 16,059 bases upstream of the predicted transcription
start site (TSS) [20]. For details go to the Human Genome
Browser (http://www.ncbi.nlm.nih.gov/gene?cmd=Retrie-
ve&dopt=Graphics&list_uids=9700) and find the TSS at
position 53,662,083 (+ strand) of the NC_000012.11
Chromosome 12 Reference GRCh37.913 Primary Assem-
bly. The Champion ChIP Transcription Factor Search Por-
tal based on SABiosciences’ proprietary database known
as DECODE (DECipherment Of DNA Elements) was used
to identify the putative c-MYB binding site within the
Espl1 promoter (for more information see http://www.sa-
biosciences.com/chipqpcrsearch.php?app=TFBS). A hypo-
thetical c-MYB binding site was found 15,623 bases
upstream of the TSS (53,646,460 - 53,646,470) and thus, is
located between both TP53 sites (see Fig. 4a). In order to
determine whether the putative c-MYB binding site of the
ESPL1 promoter can actually bind the c-MYB protein, we
performed electrophoretic mobility shift assays (EMSA).
Native nuclear extracts prepared from exponentially grow-
ing BV-173 cells were incubated with a FITC-labeled
double stranded oligonucleotide (Fig. 4b lane 1) featuring
the c-MYB binding site of the ESPL1 promoter. As shown
in Fig. 4b left panel, addition of nuclear extract to the
Table 1 Percent changes (Δ-values are differences between means) in c-MYB and ESPL1/Separase transcript and protein levels under
IM treatment when compared to corresponding untreated cells
Cell line, dose and period of treatment c-MYB transcript levelsa c-MYB protein levelsb ESPL1 transcript levelsa Separase protein levelsb
LAMA-84, 2.5 μM IM, 24 h −88.8 ± 4.4, p < 0.0001 −25.7 ± 9.6, p = 0.0233 −90.3 ± 3.3, p < 0.0001 −75.8 ± 16.8, p = 0.0064
K562, 1 μM IM, 24 h −82.4 ± 4.4, p < 0.0001 −37.1 ± 9.6, p = 0.0082 −25.0 ± 9.7, p = 0.0328 −53.1 ± 4.4, p = 0.0015
U937, 5 μM IM, 48 h −9.1 ± 2.9, p = 0.0363 +9.8 ± 10.2, p = 0.3942 −8.1 ± 9.5, p = 0.4198 −10.5 ± 11.2, p = 0.3775
a Δ-values [%] were calculated from at least triplicate qRT-PCR experiments and were normalized to the housekeeping gene Gus
b Δ-values [%] are derived from at least triplicate Western blot immunostaining experiments. All protein values were normalized to Actin as loading control
Abbreviations: d days, h hours, IM imatinib; + increase, − decrease
Fig. 2 Comparative analysis of c-MYB and ESPL1 transcript levels in
paired cDNA samples of CML patients (n = 5) before and under IM
therapy. Percent changes (Δ-values are differences between means)
are shown corresponding to expression level changes within paired
samples, each pair derived from the same patient at differing time
points (sample at diagnosis (before IM treatment) vs. sample after
major molecular response (MMR) achievement under IM therapy).
All transcript levels were normalized to Gus and represent mean
values of triplicate qRT-PCR assays
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FITC-labeled oligonucleotide (lane 2) led to the formation
of an oligo/protein complex with retarded electrophoretic
migration (shift). Addition to the incubation mix of a
100fold molar excess of unlabeled c-MYB binding site
oligonucleotide successfully competed with the formation
of the shifted signal (lane 3). For corroboration of c-MYB
protein binding, the native agarose gel was blotted under
denaturing conditions followed by immunostaining with
an anti-c-MYB antibody (right panel). The contribution of
c-MYB to the shift signal (lane 2) was confirmed. In
addition, the unlabeled competitor oligonucleotide (lane
3) appeared as shifted signal as well confirming specific
abrogation of the FITC signal (left panel, lane 3) by the
unlabeled competitor DNA. The second and lower band
may be due altered electrophoretic mobility of at least
some of the native oligo/c-MYB complexes after addition
of 100fold excess of the unlabelled competitor. To
demonstrate in vivo binding of c-MYB protein to the
putative c-MYB recognition site located within the
ESPL1 promoter we performed ChIP experiments on
BV-173 cells. As shown in Fig. 4c a significant enrich-
ment of ESPL1 promoter-related target DNA was ob-
served when using a c-MYB-specific IgG antibody for
chromatin immunoprecipitation when compared to the
unspecific IgG antibody control. In summary, our in
vitro and in vivo data suggest that c-MYB directly binds
to the ESPL1 promoter and positively regulates ESPL1/
Separase expression.
Discussion
In search for transcriptional mechanisms that may explain
the previously observed IM-associated downregulation of
Separase protein levels in CML [13] followed by posttrans-
lational hyperactivation of Separase proteolytic activity, we
have analyzed the conditional context between c-MYB
expression, Separase and IM treatment. We found that the
transcription factor c-MYB, known to play a pivotal role in
proliferation, survival and differentiation of normal myeloid
progenitors, is a direct positive regulator of Separase ex-
pression. Specifically, we demonstrated by EMSA (Fig. 4b)
and ChIP that c-MYB interacts with a putative c-MYB
binding motif located within the ESPL1 promoter. In fact,
in all tested CML cell lines (K562, LAMA-84, BV-173) and
in primary cells from CML patients coinciding c-MYB
and ESPL1/Separase expression levels irrespective to
therapeutic treatment (IM) and silencing (siRNA) con-
ditions (Figs. 1, 2 and 3) were observed. This suggests
that the ESPL1 promoter is under transcriptional con-
trol of the transcription factor c-MYB concurring with
former results of Kohmura and coworkers who found a
downregulation of c-MYB mRNA levels in K562 cells
after incubation with IM [55].
Our results further coincide with previous studies
reporting that p210BCR-ABL functions as enhancer of
c-MYB expression and plays an important role in BCR-
ABL-dependent leukemogenesis as the leukemic blast
cells appear to rely on high levels of c-MYB protein
more than normal progenitors [37, 45]. Moreover, c-
MYB promotes centriole duplication and, when mutated,
can lead to centrosome amplification as demonstrated in
mouse and Drosophila model systems [56, 57]. Previous
microarray data point to c-MYB as part of the regulatory
network associated with CML progression including
clonal evolution and genetic instability [58, 59].
The positive regulatory impact of c-MYB on ESPL1/
Separase expression explains well the observations of
Patel and Gordon who found abnormally high Separ-
ase expression levels in CML cells of chronic and
blast phase when compared to normal CD34+ cells. It
was then speculated that BCR-ABL expression may
Fig. 3 Separase expression after c-MYB silencing by RNAi in BV-173 and LAMA-84 cells. BV-173 (panel a) and LAMA-84 cells (panel b) were treated with
negative control siRNA (nc) and c-MYB-specific siRNA (siRNA). C-MYB transcript levels are measured by qRT-PCR (left column). The house-keeping gene
Gus (beta-glucuronidase) served as internal standard. C-MYB and Separase regulation on protein levels were determined by quantitative Western blot
immunostaining experiments 48 h post transfection (middle and right columns, respectively). Corresponding representative Western blot images are
shown in the very right panels of A and B. Actin served as loading control for Western blot immunostaining. All densitometric data are derived from
at least triplicate experiments
Prinzhorn et al. Biomarker Research  (2016) 4:5 Page 5 of 9
upregulate ESPL1/Separase and influence the occur-
rence of centrosomal aberrations [60].
Our data provide the first proof of direct regulatory rela-
tionship between BCR-ABL, c-MYB and ESPL1/Separase
and give a plausible mechanistic explanation on how BCR-
ABL may trigger dislocation between the centrosome-
centriole cycle and the cell cycle in CML contributing to
clonal evolution and genomic instability. The therapeutic
administration of IM “normalizes” c-MYB protein levels -
as shown in LAMA-84 and K562 cells (Fig. 1) - either by
slowing down the transcriptional rate of c-MYB or by
antagonizing enhanced c-MYB protein stability elicited by
BCR-ABL via the PI-3 K/AKT pathway [36, 55]. The antic-
ipated decrease of c-MYB protein levels after IM treatment
is also in line with data of Flamant and coworkers who
demonstrated that the drug results in a rapid increase in
the expression of regulatory microRNAs such as miR-150
that is a strong negative regulator of c-MYB protein
expression [61, 62].
Conclusions
In conclusion, our data suggest that ESPL1/Separase is a
regulatory target of c-MYB and that c-MYB expression is
modulated by IM treatment. Therefore, c-MYB, known to
be required for BCR-ABL-dependent transformation of
hematopoietic progenitors and leukemogenesis, may also
influence Separase-related proteolytic events such as
chromosomal segregation and centriole duplication, the
ordered course of which is essential for maintenance of
centrosomal and genomic stability.
Methods
Cell lines and culture conditions
Four human cell lines (K562, LAMA-84, BV-173, U937)
were investigated. Of these, K562, LAMA-84 and BV-173
are BCR-ABL-positive IM responsive CML cell lines.
U937 cells served as BCR-ABL-negative control cells. All
cell lines were obtained from the DSMZ (German Collec-
tion of Microorganisms and Cell Cultures, Braunschweig,
Germany) and were cultured in RPMI-1640 medium
supplemented with 10 % fetal bovine serum and 1 %
penicillin-streptomycin (Gibco/Invitrogen, Karlsruhe,
Germany) at 37 °C in 5 % CO2 atmosphere. Exponentially
growing cells were used in at least triplicate experiments.
Patients and ethics statement
Paired cDNA samples of randomly chosen CML patients
(n = 5) from the German CML-Study IV (registered at
www.clinicaltrials.gov as # NCT00055874) were investi-
gated by qRT-PCR. Each sample pair was derived from
peripheral blood of the same patient at the time point of
diagnosis (before IM treatment) and after achievement
of major molecular response (MMR) under IM therapy.
Blood sampling was performed in the context of regular
Fig. 4 Electrophoretic mobility shift assay (EMSA) using synthetic
ESPL1 promoter-derived c-MYB binding site probes and Chromatin
immunoprecipitation (ChIP). a Schematic drawing depicting the
ESPL1 Separase promoter and location of predicted regulatory
DNA motifs (drawing not to scale) (Pati 2008). The arrow shows
the predicted transcription start site (TSS). Abbreviations: TATA, TATA
box; PRE, progesterone responsive element; ERE, estrogen responsive
element; p53, p53 binding element; c-MYB, predicted c-MYB binding
element. Numbers denote upstream distances with respect to the TSS.
b A FITC-labeled double stranded DNA oligonucleotide corresponding
to the putative c-MYB binding site of the ESPL1 promoter was
incubated with native BV-173 nuclear extract. DNA/protein complexes
were resolved on a 0.5 % TBE 1.0 % native LE/GTG agarose gel. The left
panel (tonal inversion) shows FITC-related fluorescence signaling of the
gel before blotting, the right panel depicts the corresponding anti-c-
MYB Western blot immunostaining. The lanes represent: lane 1, DNA
target (FITC-labeled oligonucleotide) without nuclear extract; lane
2, DNA target with nuclear extract; lane 3, DNA target with nuclear
extract and with 100fold molar excess of analogous unlabeled
oligonucleotide as binding competitor. c ChIP analysis of BV-173 cells.
DNA fragments immunoprecipitated by anti-c-MYB IgG and a non-
binding control IgG were amplified by qRT-PCR. Results are expressed
as percentage of input (average). ChIP results are derived from at least
triplicate qRT-PCR measurements
Prinzhorn et al. Biomarker Research  (2016) 4:5 Page 6 of 9
therapeutic monitoring. The procedure followed the dec-
laration of Helsinki and was approved by the IRB/Medi-
zinische Ethikkommision II der Medizinischen Fakultät
Mannheim der Ruprecht-Karls-Universität Heidelberg.
(http://www.umm.uni-heidelberg.de/inst/ethikkommissi
on, # 2013-509 N-MA from 2013-02-21). Written in-
formed consent was obtained from all patients. Two
female and three male patients, all with b3a2 BCR-ABL fu-
sion type, were analyzed. The median age was 58 years
(range, 47 to 78). Mean time between diagnosis and sam-
pling of the second specimen from the same patient after
achievement of MMR under IM treatment was 3.6 years
(range, 2 to 6.5).
IM treatment
Cells were treated with IM (Biomol GmbH, Hamburg,
Germany) in concentrations of 1 to 5 μM for 24 h
(K562, LAMA-84) and 48 h (U937) according to the ra-
tionale pointed out in references [13, 35]. Untreated cells
served as controls.
Western blot analysis, antibodies
Western blot immunostaining of Separase and Actin
was performed as described previously [13]. For c-MYB
detection, an anti-c-MYB monoclonal rabbit antibody
(ab45150; Abcam, Cambridge, UK) at a dilution of
1:10,000 was used. Signals were visualized with a Chemi-
Doc™ XRS+ System (BIO-RAD, München, Germany)
after secondary antibody staining (goat anti-rabbit IgG
HRP conjugated antibody (1:10,000; Santa Cruz Biotech-
nology Inc., Heidelberg, Germany) utilizing SuperSignal
West Femto Maximum Sensitivity Substrate (Thermo
Fisher Scientific, Bonn, Germany). Image acquisition and
densitometric analysis was performed using Image Lab
Software (version 3.0.1, BIO-RAD). All values were nor-
malized with Actin as loading control. Image cropping
and tonal adjustments across the entire image were per-
formed with Adobe Photoshop CS4 (Adobe Systems
Inc., San Jose, CA, USA).
RNA extraction and quantification of ESPL1 and c-MYB
transcripts by qRT-PCR
Total RNA was extracted using RNeasy kit (Qiagen,
Hilden, Germany) and reverse transcribed using Super-
script II kit (Gibco/Invitrogen). For quantification of
ESPL1 and c-MYB transcript levels, the commercial
Hs_MYB_1_SG and Hs_ESPL1_1_SG QuantiTect Primer
Assays (Qiagen) were employed according to the instruc-
tions (two-step Light Cycler 480 protocol) of the manufac-
turer, respectively. For normalization, the housekeeping
gene beta-glucuronidase (Gus, NM_000181, GUSB, primer
set Hs_GUSB_1_SG, QuantiTect Primer Assay, Qiagen)
was amplified. QRT-PCR was performed with the Roche
LightCycler 480 System, using LC480 DNA Master SYBR
Green and the standard LightCycler protocol (Roche
Diagnostics, Mannheim, Germany). Relative transcript
levels calculated from triplicate measurements were calcu-
lated by the 2-ΔΔCT method with values normalized to Gus
and relative to transcription in untreated control cells [63].
C-MYB silencing by siRNA
C-MYB-specific siRNA (FlexiTube GeneSolution
GS4602 for c-MYB) was purchased from Qiagen. As
negative controls the same cells were transfected with
AllStars Negative Control siRNA (Qiagen), a nonsilen-
cing siRNA with no homology to any known mamma-
lian gene. Transfection was accomplished using the
Nucleofector manual (program T016, Lonza GmbH,
Köln, Germany). For siRNA treatment, 1.5x106 cells
were resuspended in 100 μl Cell Line Nucleofector Solu-
tion V (Lonza) containing 18 μl Supplement S Solution
(Lonza). The siRNA was added to a final concentration
of 0.01 nmol per 106 cells. 24 h after transfection c-MYB
transcript levels were analyzed by qRT-PCR. Protein ly-
sates for Western blot immunostaining experiments
were prepared 48 h after transfection.
ESPL1 promoter electrophoretic mobility shift assay
(EMSA)
Native nuclear extracts were prepared from BV-173 cells
according to a rapid micropreparation method [64]. FITC-
labeled oligonucleotides (32mers) corresponding to the c-
MYB-binding site sequence in the human ESPL1 promoter
(Human genome browser http://www.ncbi.nlm.nih.gov/
gene?cmd=Retrieve&dopt=Graphics&list_uids=9700), NC_
000012.11 chromosome 12 reference GRCh37.p13 primary
assembly; c-MYB binding position: chr12: 53,646,460 -
53,646,470) were synthesized by Sigma GmbH (Rödermark,
Germany). Oligonucleotide sequences (c-MYB binding se-
quence underlined) were: MYB_sense, FITC-CTCCCA
CCCACCCAACTGGTCCCTCCGGTCTG; MYB_anti-
sense, FITC-CAGACCGGAGGGACCAGTTGGGTGGGT
GGGAG. EMSA was performed using the EMSA kit (order
no. E33075) of Life Technologies GmbH (Darmstadt,
Germany) according to the instructions of the manufac-
turer. In brief, 2 μg of nuclear extract were mixed with
binding buffer prior to addition of 30 ng of annealed double
stranded oligonucleotide corresponding to the c-MYB
binding site within the ESPL1 promoter. After incubation
for 20 min at RT, 2 μl of EMSA loading dye was added and
the DNA/protein complexes were resolved by electrophor-
esis (80 V for 90 min) on a 0.5 % TBE 1.0 % native LE/
GTG agarose gel. Detection of FITC-labeled DNA oligonu-
cleotides was performed using a ChemiDoc™ XRS+ System
(BIO-RAD). Consecutively, the same agarose gel was blot-
ted onto Immobilon-P membrane (Millipore, Bedford,
USA) using a Trans Blot SD semi-dry electrophoretic trans-
fer cell (BIO-RAD) at 15 V (current limit at 5 mA/cm2) for
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30 min. C-MYB Protein detection was performed as
described in the Western blot analysis section.
Chromatin immunoprecipitation (ChIP)
ChIP was performed using the EpiTect ChIP OneDay Kit
(#334471, Qiagen, Hilden) according to the instructions of
the manufacturer. In brief, 1.5x106 BV-173 cells per sample
were lysed and sonicated (5 times 6 s, 0.5 W) using the
Vibra-Cell™ system (Sonics, Newtown, USA). Immunopre-
cipitation was performed with an anti-c-MYB antibody
(ab17851, Abcam, Cambridge, UK) and an unspecific
control IgG1 control antibody (ab91353, Abcam) ac-
cording to the manual. For quantification of the immu-
noprecipitated DNA target, the ChIP qPCR Primer
Assay GPH1003144(+)02A (Sabioscience/Qiagen) was
applied employing the Roche LightCycler 480 System,
using LC480 DNA Master SYBR Green and the stand-
ard LightCycler protocol as already described (Roche
Diagnostics, Mannheim, Germany). Results derived
from triplicate experiments were expressed as percent-
age of input sample taken before immunoprecipitation
during the ChIP procedure. Therefore, the Ct values of
the IP fractions were normalized to the input fraction.
Statistical analysis
Statistical significance of unpaired data was analyzed
by the Student’s t-test using the GraphPad Prism soft-
ware version 6.0 (GraphPad Inc., La Jolla, USA).
Values of p < 0.05 were considered significant.
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